Kexing BiopharmEN
NEWS AND INFORMATION
Home / News / News and Innovation / Kexing Biopharm...

Kexing Biopharm and Easton Biopharmaceuticals Jointly Expand Overseas Market for Apalutamide Tablets

Article source:Kexing BiopharmOct 17,2025View: 2611

This year, Kexing Biopharm Co., Ltd. (stock code: 688136.SH), a leading domestic pharmaceutical enterprise in overseas expansion, signed a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd., a renowned innovative enterprise. Recently, the two parties reached an exclusive authorization agreement for the overseas commercialization of Easton Biopharmaceuticals' generic apalutamide tablets in more than ten countries, including Indonesia, Egypt, Saudi Arabia, and Colombia. This agreement further deepens their collaboration, promoting the launch of this blockbuster drug in the prostate cancer treatment field across high-potential markets in Southeast Asia, the Middle East, and Latin America, thereby benefiting more patients.


Kexing Biopharm and Easton Biopharmaceuticals Jointly Expand Overseas Market for Apalutamide Tablets


Clinical Demand Drives Growth Potential in Emerging Markets


Easton Biopharmaceuticals' apalutamide tablets received the Drug Registration Certificate approved and issued by the National Medical Products Administration in May this year. The indications include adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) and adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis. As a second-generation non-steroidal androgen receptor (AR) inhibitor, apalutamide tablets are recommended by multiple authoritative guidelines both domestically and internationally, with its clinical value widely recognized.

The 2024 edition of the Global Cancer Statistics 2022 report, compiled jointly by the International Agency for Research on Cancer of the World Health Organization and the American Cancer Society, indicates that prostate cancer ranked among the top ten in both the number of new global cancer diagnoses and cancer deaths in 2022, accounting for 7.3% and 4.1%, respectively. In developing countries, constrained by diagnostic and treatment capabilities as well as payment affordability, there remains a significant gap in the accessibility of prostate cancer therapies. This has led to a surge in demand for high-quality generic drugs offering superior cost-effectiveness, representing an untapped "blue ocean" market ripe for development.


In-Depth Cooperation, Jointly Going Global


Previously, Kexing Biopharm had introduced enzalutamide soft capsules from Jiangxi Kvvit Pharmaceutical Co., Ltd. This collaboration on Easton Biopharmaceuticals' apalutamide tablets marks the second high-end drug in its prostate cancer portfolio, gradually strengthening its overseas product line in this therapeutic area.

Easton Biopharmaceuticals is a high-tech enterprise driven by R&D innovation, integrating the research, development, production, and sales of chemical raw materials, high-end chemical drugs, and biologics. This partnership will leverage Easton Biopharmaceuticals' R&D and industrialization expertise to ensure a stable supply of apalutamide tablets. Meanwhile, through Kexing Biopharm's overseas commercialization platform, it will provide comprehensive support for the drug's registration applications, market strategy development, and promotional activities in target markets. The two parties complement each other's strengths in a powerful alliance, generating synergistic effects.

Currently, Kexing Biopharm's global sales network spans approximately 70 countries and regions. Since the beginning of this year, multiple collaborative products have successively obtained marketing approvals in various countries, with the company's overseas localized marketing capabilities continuing to advance.


Kexing Biopharm and Easton Biopharmaceuticals Jointly Expand Overseas Market for Apalutamide Tablets


Kexing Biopharm adheres to the principle of "Innovation + Internationalization," dedicated to delivering high-quality, cost-effective medicines to patients worldwide. Looking ahead, the company will fully leverage its global resources and localized operational expertise, partnering with collaborators to deeply cultivate international markets.


LABEL:
Related News